Navigation Links
Sinovac Reports Unaudited Second Quarter 2011 Financial Results
Date:8/12/2011

nses as a percentage of sales for the six-month period of 2011 were 44.7%, compared to 48.3% during the same period of the prior year.  Excluding pandemic flu vaccine sales, SG&A as a percentage of sales were 71.9% and 60.2% for the first half year and prior year same period, respectively. The increased SG&A was mainly related to the expansion of sales team and increased spending on sales promotion on the private pay market.  

Net research and development expenses for the six-month period of 2011 were $4.4 million, compared to $2.8 million in the same period of 2010. The increased R&D expenses in the six-month period of 2011 were primarily related to the continued development of the pipeline vaccines, including the expenses for the EV71 vaccine with the Phase II clinical trial underway, the trial production of the animal rabies vaccine and mumps vaccine, and other R&D projects.

Depreciation of property, plant and equipment and amortization of license and permits for the six-month period of 2011 were $846,000, compared to $511,000 for the same period of last year. The change compared to 2010 was primarily attributable to amortization on the Changping production facility, which started to amortize in September 2010 and higher depreciation for Tangshan Yian's new animal production line.

Total operating expenses for the six-month period of 2011 were $14.2 million, compared to $10.3 million in the comparative period of 2010.

The operating loss for the six months ended June 30, 2011 was $300,000, compared to an operating income of $1.8 million for the same period of the prior year. The year over year change was primarily attributable to the lower gross margin due to the product mix. Excluding the recognition of revenue coming from pandemic flu vaccines of prior order, the year over year change was primarily attributable to the increased R&D expenses, SG&A expenses and depreciation of property, plant and equipm
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Sinovac Announces Management Changes
2. Sinovac Holds 2011 Annual Shareholders Meeting
3. Sinovac Appoints Kenneth Lee to Board of Directors
4. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
5. Sinovac Reports Unaudited First Quarter 2011 Financial Results
6. Sinovac Presents at Two Investor Conferences in May 2011
7. Sinovac Files Annual Report on Form 20-F
8. Sinovac Participates in UBS Greater China Healthcare Corporate Day
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
11. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP ... bellwether trial will commence October 13, 2015. ... the 510K fast-track approval program, Zimmer NexGen knee implant ... only requires that companies provide evidence that the product ... in order to gain permissions. In ...
(Date:9/2/2015)... SAN DIEGO , Sept. 2, 2015  Neurocrine ... Tim Coughlin , Chief Financial Officer of Neurocrine ... Conference in New York City . ... September 9 at 11:25am ET (8:25am PT).  The presentation ... Company,s website at http://www.neurocrine.com .   ...
(Date:9/2/2015)... QC , Sept. 2, 2015 Demers Ambulances ... (EEP) Inc. as their new dealer for the states of ... and Tennessee . "This ... customers," said Benoit Lafortune , Executive Vice-President for Demers ... Mississippi and Alabama ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
... Animal Health has launched its second product in the ... milbemycin oxime), a broad-spectrum parasiticide that kills fleas and ... infestations, the prevention of heartworm disease and the treatment ... in dogs and puppies 8 weeks and older, and ...
... 17, 2011 SFA Marketing today announced a ... exclusively to working with medical device manufacturers. SFA ... more than 20 years experience working with clients ... (Logo: http://photos.prnewswire.com/prnh/20110117/NY30375LOGO) "In response ...
Cached Medicine Technology:Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
(Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... The Generic Pharmaceutical Association (GPhA) will discuss the results ... healthcare market intelligence company, revealing that generic pharmaceutical utilization has ... system in the last decade., What: ... ...
... Suction Provides Permanent Reduction of Excessive Sweat and Smells , ... ... sweating and body odor affects 176 million people and in most ... breakthrough procedure, Hypo Lipo , ( Axillary Curettage Suction ) ...
... 7 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... quarter ended March 31, 2009. "Our focus for the ... the NDA submission for pixantrone while we implemented final ... needed operating capital on the least dilutive terms possible ...
... 20% to $0.49 per outstanding common share from ... in Q1 2008)- Improved average monthly revenue per ... occupancy was 88.7%, down from 90.0% in Q1 ... to $497.9 million- Improved Facility Operating Income by ...
... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
... 125,000-member Indiana American Legion today challenged the Indiana General ... plainly on behalf of the youngsters at the Indiana ... on legislators to "not use the current budget impasse ... announced by the Indiana State Department of Health, would ...
Cached Medicine News:Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 2Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 2Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 3Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 4Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 5Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 7Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 8Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 9Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 10Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 11Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 12Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 13Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 14Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 15Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 16Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 17Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 18Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 19Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 20Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 21Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 22Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Legion Demands 'Courage' From Legislators in Battle Over Children's Home 2
... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
Medicine Products: